Skip to content Carb-X
Carb-X
Boston University
Mobile Menu Toggle navigation
  • Sign Up
  • Contact
  • Twitter
  • LinkedIn
Carb-X
Boston University
Boston University
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Omnibus Solicitation
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Applicant Questions
  • Resources
    • CARB-X Connect
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Media Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
  • Events
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Omnibus Solicitation
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Applicant Questions
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Media Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
  • Events
  • Contact
  • Legal

Portfolio Company

  • Portfolio
  • >
  • Gallery
SpeeDx

SpeeDx, Sydney, Australia
https://plexpcr.com

Resistance Plus InSignia
RAPID POC ID/AST

Diagnostic for Chlamydia trachomatis and Neisseria gonorrhoeae

SpeeDx has developed a rapid, molecular test using polymerase chain reaction (PCR) technology called InSignia™, to assist in detecting chlamydia and active infection of gonorrhoea; additionally, through susceptibility testing, the technology will identify the best antibiotic choice for treatment of gonorrhea. SpeeDx’s technology would be combined with a battery-powered, simple-to-use device developed by another company, QuantuMDx, that could be used in remote or low-resource settings around the world as a point-of-care diagnostic. The SpeeDx technology would be ported onto the QuantuMDx Q-POC™ and the goal is to develop an affordable test to detect Chlamydia trachomatis and Neisseria gonorrhoeae in under an hour, and to determine the susceptibility of the gonorrhea bacteria to three orally administered antibiotics that are generally readily available in low-and middle-income countries (LMICs): cefixime, ciprofloxacin, and azithromycin.

Current Development Stage: Feasibility

CARB-X Investment: Initial investment of up to $1.8m with potential option payments up to $1.9m.

Initial CARB-X Investment Date: April 1, 2021

Read the Spotlight on Science about SpeeDx

Carb-X

Led by Boston University

Copyright 2023

  • Contact
  • Careers
  • Site Credits
  • Legal
  • Twitter
  • LinkedIn

Copyright 2023